• Sign up to our Free Newsletter
  • Contact Us
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Month: June 2022

Finance

4D pharma Receives Notice of Delisting From Nasdaq

June 29, 2022 Microbiome Times

Source: 4D Pharma 4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announced that on June 27, 2022, it received written […]

Finance

Vedanta Unveils State-of-the-Art Manufacturing Facility

June 29, 2022 Microbiome Times

Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, announced the opening of a new facility designed to manufacture clinical and commercial supply for its therapeutic portfolio, […]

Editor's Choice

Fecal Microbiota Transplantation (FMT): Global Industry and Regulatory Overview

June 27, 2022 Luis Gosálbez

First described in the 4th Century in China, practiced since the 1950’s and re-discovered relatively recently [1][2], Fecal Microbiota Transplantation (FMT) or simply Fecal Transplant is a therapeutic approach in which more or less processed […]

Finance

4D Pharma Update on Suspension of Trading in the Company’s ordinary shares

June 24, 2022 Microbiome Times

Source: 4D Pharma 4D pharma plc (AIM: DDDD, Nasdaq: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, provides an update to the […]

Pharma & Human Health

Bacthera: Enabling the Live Biotherapeutic Industry

June 20, 2022 Microbiome Times

Bacthera tailor live biotherapeutic product services to meet your needs, whether you are an early start-up, a fully established biotech company, or part of a pharma company working with live biotherapeutic products. We offer a […]

Pharma & Human Health

Unprecedented case series advances promise of phage therapy

June 16, 2022 Microbiome Times

An international team of researchers, led by scientists at University of California San Diego School of Medicine and the University of Pittsburgh, report promising results from the largest case series yet of patients treated with […]

Pharma & Human Health

Seres Therapeutics Announces Confirmatory Results From Ser-109 Ecospor Iv Open-Label Study In Recurrent C. Difficile Infection

June 8, 2022 Microbiome Times

Seres Therapeutics, Inc. (Nasdaq: MCRB) announced confirmatory results from ECOSPOR IV, an open-label study for SER-109, an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). The overall safety profile observed […]

Pharma & Human Health

Pherecydes Pharma Obtains AAC Early Access Program Approval From the ANSM for its anti-Staphylococcus aureus Phages

June 6, 2022 Microbiome Times

Pherecydes Pharma (Paris:ALPHE) (FR0011651694 – ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that it has been granted AAC Early Access Program approval by the […]

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • New standards in sensitivity and accuracy for microbiome research
    September 20, 2023
  • Integrating Microbiome and Dietary Data: Microbiome Data Congress 2023
    August 22, 2023
  • Distinguishing Strains in Microbiome Samples: Considerations and Challenges
    July 19, 2023
  • Proven Complementary Effect of Probiotic Yeast and Bacteria
    June 21, 2023
  • Microbiome drug development: Analysis of the historical pipeline reveals promising areas and bottlenecks
    May 25, 2023
sign up

Sign up to the Microbiome Times newsletter